Cipla Limited
CIPLA
Ранг среди акций
#1810
Cipla Limited, along with its associated entities, operates as a global... Cipla Limited, along with its associated entities, operates as a global pharmaceutical enterprise, specializing in the creation and distribution of a wide array of medicinal products. Its extensive portfolio includes both active pharmaceutical ingredients (APIs) and a diverse range of finished formulations, addressing numerous therapeutic areas such as cardiovascular diseases, metabolic disorders, HIV, respiratory conditions, urology, oncology, pediatric health, infectious diseases, critical care, hepatitis, women's health, ophthalmology, and neuropsychiatry. The company maintains a strong focus on respiratory treatments, offering various inhalers, nasal sprays, injectables, and biosimilars. Cipla has also forged significant partnerships, including a licensing arrangement with Merck & Co., Inc. for the manufacturing and commercialization of the investigational oral antiviral drug Molnupiravir, and a separate license agreement with Eli Lilly and Company for baricitinib, indicated for COVID-19. Furthermore, it collaborates with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for Molnupiravir's clinical trials. Established in 1935, Cipla's corporate headquarters are located in Mumbai, India.
Цена акции
$14.61
Последняя синхронизация: 2026-10-19
Рыночная капитализация
$11.81B
Изменение (1 день)
-0.11%
Изменение (1 год)
-21.65%
Страна
IN
Торговля Cipla Limited (CIPLA)
Категория
Healthcare
Прибыль Cipla Limited (CIPLA)
Прибыль на Jun 2026 TTM: $499.57M
Согласно последним финансовым отчетам Cipla Limited, текущая прибыль компании составляет $499.57M. В 2024 году компания получила прибыль $683.63M, больше, чем прибыли за 2023, которая составила $491.08M. Отображаемая прибыль на этой странице — это прибыль до уплаты процентов и налогов, или просто EBIT.
История прибыли компании Cipla Limited с 2004 по 2026
Прибыль в конце каждого года
| Год | Прибыль | Изменить |
|---|---|---|
| 2026 (TTM) | $499.57M | -37.16% |
| 2025 | $794.95M | 16.28% |
| 2024 | $683.63M | 39.21% |
| 2023 | $491.08M | 7.11% |
| 2022 | $458.50M | 2.41% |
| 2021 | $447.69M | 58.29% |
| 2020 | $282.83M | -4.75% |
| 2019 | $296.94M | 16.00% |
| 2018 | $255.98M | 36.61% |
| 2017 | $187.39M | -27.61% |
| 2016 | $258.87M | -0.84% |
| 2015 | $261.05M | -3.94% |
| 2014 | $271.76M | -29.32% |
| 2013 | $384.50M | 34.66% |
| 2012 | $285.52M | 9.46% |
| 2011 | $260.85M | -11.65% |
| 2010 | $295.26M | 67.39% |
| 2009 | $176.40M | -15.76% |
| 2008 | $209.41M | 12.35% |
| 2007 | $186.39M | 16.95% |
| 2006 | $159.38M | 35.23% |
| 2005 | $117.85M | 26.61% |
| 2004 | $93.09M | 0.00% |
Прибыль схожих компаний или конкурентов
| Компания | Прибыль | Разница в прибыли | Страна |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 253.21% |
IN
|
